{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+protein&page=34", "query": { "intervention": "Normal protein", "page": 34 }, "page_size": 10 }, "pagination": { "page": 34, "page_size": 10, "total_count": 2504, "total_pages": 251, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+protein&page=35&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+protein&page=33&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T22:02:46.757Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04546009", "title": "A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer" ], "interventions": [ { "name": "Giredestrant", "type": "DRUG" }, { "name": "Giredestrant-matched Placebo", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Letrozole-matched Placebo", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "LHRH Agonist", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 992, "start_date": "2020-10-09", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-26T22:02:46.757Z", "location_count": 37, "location_summary": "Fountain Valley, California • Long Beach, California • San Leandro, California + 32 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "San Leandro", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Walnut Creek", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04546009" }, { "nct_id": "NCT03998709", "title": "Effect of Fasting Free Fatty Acids and Fasting Glucose on 1st and 2nd Phase Insulin Secretion", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Somatostatin", "type": "DRUG" }, { "name": "Dextrose", "type": "OTHER" }, { "name": "Insulin", "type": "DRUG" }, { "name": "Intralipid", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "25 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "25 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2020-02-01", "completion_date": "2022-07-31", "has_results": false, "last_update_posted_date": "2022-09-09", "last_synced_at": "2026-10-26T22:02:46.757Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03998709" }, { "nct_id": "NCT00072384", "title": "Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Intraocular Retinoblastoma" ], "interventions": [ { "name": "liposomal vincristine sulfate", "type": "DRUG" }, { "name": "cryosurgery", "type": "PROCEDURE" }, { "name": "laser surgery", "type": "PROCEDURE" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "17 Years", "sex": "ALL", "summary": "Up to 17 Years" }, "enrollment_count": 30, "start_date": "2007-04-16", "completion_date": "2021-06-30", "has_results": true, "last_update_posted_date": "2021-07-30", "last_synced_at": "2026-10-26T22:02:46.757Z", "location_count": 11, "location_summary": "Arcadia, California • Downey, California • Los Angeles, California + 7 more", "locations": [ { "city": "Arcadia", "state": "California" }, { "city": "Downey", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00072384" }, { "nct_id": "NCT00243009", "title": "Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1, "start_date": "2005-06", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2012-05-28", "last_synced_at": "2026-10-26T22:02:46.757Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00243009" }, { "nct_id": "NCT01673087", "title": "Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stress" ], "interventions": [ { "name": "Metyrapone", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Cortrosyn", "type": "DRUG" }, { "name": "Corticorelin ovine triflutate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 256, "start_date": "2012-10", "completion_date": "2017-08-15", "has_results": false, "last_update_posted_date": "2018-04-23", "last_synced_at": "2026-10-26T22:02:46.757Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01673087" }, { "nct_id": "NCT02217345", "title": "Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nonalcoholic Fatty Liver Disease (NAFLD)" ], "interventions": [ { "name": "Growth hormone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 131, "start_date": "2017-06-02", "completion_date": "2021-09-13", "has_results": true, "last_update_posted_date": "2022-11-22", "last_synced_at": "2026-10-26T22:02:46.757Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02217345" }, { "nct_id": "NCT02998775", "title": "Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Hepatic Impairment; Renal Impairment" ], "interventions": [ { "name": "Plasma Sampling", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 54, "start_date": "2016-12-02", "completion_date": "2017-07-08", "has_results": false, "last_update_posted_date": "2018-09-07", "last_synced_at": "2026-10-26T22:02:46.757Z", "location_count": 3, "location_summary": "Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02998775" }, { "nct_id": "NCT00003056", "title": "Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia", "Lymphoma", "Graft Versus Host Disease" ], "interventions": [ { "name": "cyclosporine", "type": "DRUG" }, { "name": "cyclosporine and methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baxalta now part of Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 105, "start_date": "1997-04-01", "completion_date": "2003-06-01", "has_results": false, "last_update_posted_date": "2021-05-06", "last_synced_at": "2026-10-26T22:02:46.757Z", "location_count": 12, "location_summary": "Los Angeles, California • Jacksonville, Florida • Atlanta, Georgia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Lawrence", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003056" }, { "nct_id": "NCT00220194", "title": "A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cancer of Prostate" ], "interventions": [ { "name": "leuprolide acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "San Bernardino Urological Associates Medical Group Inc", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 100, "start_date": "2003-04", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2016-10-14", "last_synced_at": "2026-10-26T22:02:46.757Z", "location_count": 1, "location_summary": "San Bernardino, California", "locations": [ { "city": "San Bernardino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00220194" }, { "nct_id": "NCT01200329", "title": "High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Palifermin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "12 Years to 70 Years" }, "enrollment_count": 81, "start_date": "2011-06", "completion_date": "2018-12-06", "has_results": true, "last_update_posted_date": "2019-12-16", "last_synced_at": "2026-10-26T22:02:46.757Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01200329" } ] }